Abstract:Abstract Dendritic cells (DCs) are professional antigen-presenting cells that are integral to the induction of primary, antigen-specific T cell responses. In the cancer setting, DCs mediate cross-priming of tumor-reactive T cells by presenting tumor antigens acquired from viable or dead cancer cells. Due to their unique functional properties, DCs have been utilized as both vectors and targets for immunological intervention in numerous diseases and are optimal candidates for vaccination protocols in cancer. In addition to their antigen presentation function(s), recent evidence suggests that DCs may also perform an innate immune effector function, with human DCs reported to mediate direct tumoricidal activity in vitro. However, the mechanism(s) by which DCs directly kill tumor cells remain unclear. The goal of this study is to further characterize the mechanism(s) associated with murine DC tumoricidal function and to determine whether and how this function may be enhanced to promote anti-tumor immune responses that translate into therapeutic effectiveness. One way we sought to enhance this DC effector function was through the genetic engineering of DCs themselves. After transduction with mIL-12 and/or mIL-18 cDNA using recombinant adenoviral vectors, DCs exhibited significantly elevated tumor killing activity. This was mediated, at least in part, by TNF ligand-receptor complexes, as demonstrated by antibody blocking assays. When injected in situ, these engineered DCs exhibited prolonged survival, in association with enhanced levels of tumor apoptosis proximal to imaged DCs and our capacity to image DC that had engulfed tumor apoptotic bodies. We also observed notable therapeutic benefits upon intratumoral delivery of these DCs in concert with an expanded in vivo repertoire of anti-tumor CD8+ T cells. In addition to DC modification, we also evaluated treatments applied to tumor cells that resulted in enhanced sensitivity to (control) DC-mediated killing. Specifically, we found that pretreatment of A20 lymphoma cells with a nitric oxide (NO) donor compound, PAPA-NO, markedly increased the sensitivity of tumor cells to consequent apoptosis mediated by DCs. This appeared to provide DCs with a preferred source of tumor antigens, with which, they were capable of activating specific T cells via a cross-presentation pathway. We have also discovered that multiple TNF family ligands participated in DC-mediated tumoricidal function and that tumor cell-expressed survivin may represent a critical downstream factor regulating the apoptotic sensitivity of tumor cells to DC-mediated apoptosis. When taken together, these studies provide novel details regarding mechanisms involved in DC anti-tumor effector function, and suggest two DC-based, combinational cancer therapies that target the effective cross-priming of therapeutic T cells. The results presented in this dissertation support an efficient model in which DCs may not only serve as the gatherers and presenters of antigens, but also the hunters as well, with tumoricidal activity mediated via TNF family ligands.

CD40-activated apoptotic tumor cell-pulsed dendritic cell could potentially elicit antitumor immune response: involvement of up-regulation of B7-H3 expression.

Regulatory Effects of CD40 Ligation on B7-H3 Expression in Murine Dendritic Cells

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Distinct Effect of CD40 and TNF-Signaling on the Chemokine/Chemokine Receptor Expression and Function of the Human Monocyte-Derived Dendritic Cells

OVEREXPRESSION OF B7-H4 IN TUMOR INFILTRATED DENDRITIC CELLS

Study of CD40 ligation tumor specific dendritic cells on mediating Th1 cells polarization

B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism

Gene Transfer of CD40-Ligand to Human Dendritic Cells Induces Growth Arrest and Apoptosis of Tumor Cells Mediated by Up-Regulated TRAIL and its Receptors.

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Fine-Tuned Expression of Programmed Death 1 Ligands in Mature Dendritic Cells Stimulated by CD40 Ligand is Critical for the Induction of an Efficient Tumor Specific Immune Response

Mechanisms of CD40-dependent cDC1 licensing beyond costimulation

Effects of CD 40-Pulsed Tumor Specific Dendritic Cells on Biological Activity of Cytokine-Induced Killer Cells

The Effects of CD40L on the Phenotypes and IL-12 Secretion of B Lymphocytes

Antigen-loaded dendritic cells and CD40L triggers the killing effects of cytotoxic T lymphocytes on K562 cells in vitro

Anti-CD40-induced Inflammatory E-cadherin+ Dendritic Cells Enhance T Cell Responses and Antitumour Immunity in Murine Lewis Lung Carcinoma

MODULATION OF TUMORICIDAL ACTIVITIES OF DENDRITIC CELLS TO ENHANCE ANTIGEN UPTAKE AND CROSS-PRESENTATION

Dendritic cells loaded with apoptotic tumor cells in the treatment of lung cancer

Study on Tumor-Specific Cytotoxicity T Lymphocytes Activated by Dendritic Cells Loaded with Apoptotic Tumor Cells

The Involvement Of Tnf-Alpha-Related Apoptosis-Inducing Ligand In The Enhanced Cytotoxicity Of Ifn-Beta-Stimulated Human Dendritic Cells To Tumor Cells

The Involvement of TNF-α-Related Apoptosis-Inducing Ligand in the Enhanced Cytotoxicity of IFN-β-Stimulated Human Dendritic Cells to Tumor Cells